查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593751

双极性情感障碍市场：按类型、按药物类别、按疾病类型、按给药途径、按分销管道、按地区、机会、预测，2017-2031 年

Bipolar Disorder Market Assessment, By Type, By Drug Class, By Disorder Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 233 Pages | 商品交期: 3-5个工作天内

价格

全球双极性情感障碍市场规模预计将从 2023 年的 50.1 亿美元成长到 2031 年的 63.5 亿美元，2024-2031 年的复合年增长率为 3.01%。双相情感障碍市场的成长是由全球双相情感障碍疾病负担不断增加、人们对心理健康意识的提高、早期有效诊断的诊断方法数量不断增加、市场参与者提供的创新产品等推动的。因素

双极性情感障碍是一种以极端情绪波动为特征的精神疾病，包括躁狂和忧郁发作。治疗通常会结合药物治疗（例如情绪稳定剂或抗精神病药物）和心理治疗（例如认知行为治疗（CBT））。个人化的方法至关重要，通常结合生活方式的改变和支持系统来帮助有效管理症状。定期监测和调整治疗计划对于实现双相情感障碍的稳定和改善生活品质至关重要。随着越来越多的人关注心理健康，治疗双相情感障碍的药物市场正在不断增长。围绕精神疾病的耻辱正在消除，更好的治疗机会也正在出现。利用穿戴式装置和人工智慧等数位工具的早期诊断进一步推动了市场成长。市场的主要课题是延长治疗时间和患者用药依从性。然而，由于市场进入者努力提供更好的替代品，市场成长持续上升。

本报告研究了全球双相情感障碍市场，按类型、药物类别、疾病类型、给药途径、分销管道、地区以及参与市场的公司概况提供了市场概述。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第 4 章 2017-2031 年全球双极性情感疾患市场展望

  • 市场规模分析与预测
  • 市占率分析及预测
  • 2023 年市场地图分析
    • 按类型
    • 按药物类别
    • 依故障类型
    • 按给药途径
    • 按分销渠道
    • 按地区

第5章 2017-2031 年北美双极性情感疾患市场展望

第6章 欧洲双极性情感疾患市场展望，2017-2031

第7章 2017-2031 亚太地区双极性情感疾患市场展望

第 8 章 2017-2031 南美洲双极性情感疾患市场展望

第 9 章 2017-2031 年中东与非洲双极性情感疾患市场展望

第10章供需分析

第11章 价值链分析

第12章 波特五力分析

第13章 PESTLE分析

第14章价格分析

第15章 市场动态

第16章市场趋势与发展

第17章 监理框架与创新

第18章 专利情况

第19章案例研究

第20章 竞争格局

  • 前5名市场领导者的竞争矩阵
  • 前5名参与企业SWOT分析
  • 前10名入市企业现状
    • AbbVie Inc.
    • GlaxoSmithKline plc
    • Eli Lilly and Company
    • Janssen Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Bristol Myers Squibb Company
    • Pfizer Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • AstraZeneca PLC

第21章 战略建议

第22章 查询及免责声明

Product Code: MX12263

Global bipolar disorder market is projected to witness a CAGR of 3.01% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.35 billion in 2031. The growth in the bipolar disorder market is anticipated to be fueled by factors like the growing disease burden of bipolar disorder worldwide, growing concerns about mental health, increased diagnostics methods for early and effective diagnosis coupled with innovative product offerings from market players.

Bipolar disorder is a mental health condition characterized by extreme mood swings, including episodes of mania and depression. Treatment typically involves a combination of medications, such as mood stabilizers and antipsychotics, and psychotherapy, including cognitive behavioral therapy (CBT). A personalized approach is essential, often incorporating lifestyle changes and support systems to help manage symptoms effectively. Regular monitoring and adjustments to the treatment plan are crucial for achieving stability and improving the quality of life for individuals with bipolar disorders. The market for pharmaceutical treatment options for bipolar disorder is on the rise owing to increased emphasis on mental health and attention being given to mental wellness these days. The stigma associated with mental diseases is now clearing up, thus opening the door to opportunities for better treatment. Early diagnostic methods that utilize digital tools like wearable devices and artificial intelligence further drive the growth in the market. The major challenge in this market is the longer duration of treatment and patient adherence to it. However, the efforts of market players to provide better alternatives keep market growth on the rise. For instance, in April 2024, Vanda Pharmaceuticals Inc. received FDA approval for its atypical antipsychotic Fanapt (iloperidone) to treat manic or mixed episodes in adults with bipolar I disorder. Based on a Phase III clinical trial involving around 400 patients, this approval demonstrated significant improvements in mania severity compared to placebo. Fanapt, previously approved for schizophrenia, offers flexible dosing and a well-established safety profile.

Growing Bipolar Disease Burden to Boost Market Demand

The rising tide of bipolar disorder has a profound implication on the demand side of this market for therapeutics. Growing awareness and more developed diagnostic practices have increased the prevalence, so more patients find treatment. Extreme mood swings characterize bipolar disorder; hence the condition continues to create continuous demand for mood stabilizers, antipsychotics, and psychotherapy. Increased loss of productivity and healthcare costs attributable to the disorder have made governments and organizations concentrate more on initiatives that improve mental health, thus pushing the growth rate even higher in the market. Advances in research and development have also resulted in novel therapies that are effective and attractive to treatment. As acceptance within society of mental health issues improves, more patients are expected to seek help, increasing overall expansion in the bipolar therapeutics market. This mix sets the bipolar disorder market up to have a great future in the coming years. For instance, as per WHO data, more than 40 million patients have bipolar disorder across the globe, and according to the latest Global Burden of Disease (GBD) study, around 2.4% of the global population is affected by bipolar disorder.

Advancements in Diagnostic Tools Drive Market Growth

Advances in diagnostic tools are also a significant growth area in the bipolar disorder market as sophisticated mechanisms increase the precision of their identification and subsequent treatments. Recent developments include a relatively simple blood test, which can diagnose as much as 30% of cases of bipolar disorder-especially in conjunction with online psychiatric assessments. This advance clarifies differences between bipolar disorder and other closely related diagnoses, such as major depressive disorder, often over-diagnosed. With growing awareness and reduced stigma, more patients seek timely diagnoses, thus fueling the market demand. Technological advancement also helps better manage patients by including mood pattern monitoring applications in the patient's smartphone. Increased diagnosis leads to interventions at earlier stages, thus better interventions and, subsequently, more drugs and therapies for the disorder of bipolar. This trend is expected to continue with further research and tools. For instance, in April 2024, SYNLAB International GmbH marked World Bipolar Day 2024 by announcing the launch of a revolutionary test for diagnosing bipolar disorder in France. The myEDIT-B test is the first clinically validated test for differentiating between bipolar disorder and unipolar depression, using RNA editing changes in patients' blood.

Mood Stabilizers Segment to Dominate With Highest Market Share

Mood stabilizers are one of the most used medications for bipolar disorder. They are effective in the stabilization of mood swings and the prevention of both manic and depressive episodes, thus holding the major share in the bipolar disorder market. Among all the discovered mood stabilizers, lithium was the first in use to treat patients with mania. It had long been used in the treatment of mania. It was known for its efficacy in reducing the frequency as well as severity of manic episodes with protection against depression. Other drugs have also been effective, the best examples being valproate and lamotrigine, though these are most effective for certain types of bipolar. They stabilize the shifting patterns of mood as much as possible, helping a person stay balanced and permitting daily functioning to improve. Adding further strength to their position as the foundation in bipolar disorder treatment is their ability to improve quality of life and prevent recurrence. For instance, several mood stabilizer drugs approved by USFDA in recent times include Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Aripiprazole (Abilify), Lurasidone (Latuda), Asenapine (Saphris), Cariprazine (Vraylar), and Lumateperone (Caplyta).

Asia-Pacific Dominates the Bipolar Disorder Market

Asia-Pacific is anticipated to register a fast CAGR and, thus, exponential growth. Compared to the historical years, the diagnosis and recognition of mental health conditions are more prevalent in Asia-Pacific now, thereby increasing the demand for efficient treatment options significantly. In addition, with the effect of continuous urbanization and a change in lifestyle increasing stress factors, more people are now approaching health professionals for solutions to these mental health issues. Improved governmental initiatives and a boost in healthcare infrastructure are also increasing psychiatric services and medications. At the same time, the Asia-Pacific region is witnessing increasing investment from pharmaceutical companies that focus on the research and development of new therapies targeted at the peculiar needs of diverse populations. Mental health is slowly eroding its stigma, and more patients are encouraged to seek treatment. As such, these factors make the Asia-Pacific market for bipolar disorder treatment a rising area and an attractive investment opportunity for stakeholders in the healthcare industry. For instance, according to the National Mental Health Survey conducted in India, the prevalence of bipolar disorder in India is 0.5%, which comes out to be affecting more than 7 million people in India.

Future Market Scenario (2024-2031F)

The rise of digital therapeutics and online cognitive behavioral therapy (CBT) offers accessible, effective management tools for patients. These platforms can reduce depressive symptoms and improve overall well-being by providing real-time support and monitoring.

Devices that monitor sleep patterns and physical activity are proving effective in managing symptoms. Research indicates that regular tracking of these factors can stabilize mood, leading to more tailored treatment approaches.

Discoveries related to specific genes, like AKAP11, provide a deeper understanding of bipolar disorder's molecular mechanisms, paving the way for novel therapies that target these pathways.

Key Players Landscape and Outlook

The market for pharmaceuticals for bipolar disorder is being catered to by several players ranging from small startups to global pharmaceutical giants. Recent market activities include innovative product launches, acquisition deals, and regulatory approvals, which are anticipated to expand the market in the forecast period.

In March 2024, Bristol Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, broadening its neuroscience portfolio. This strategic move includes the integration of KarXT (xanomeline-trospium), an innovative antipsychotic with a unique mechanism of action, which is currently under review for treating schizophrenia. Notably, KarXT is also in trials for additional indications, including Bipolar I disorder, and agitation associated with Alzheimer's disease, highlighting its potential to address a range of mental health conditions. The acquisition is expected to bolster BMS's growth trajectory, aligning with its commitment to expanding treatment options in neuroscience.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Bipolar Disorder Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Generic
      • 4.2.1.2. Branded
    • 4.2.2. By Drug Class
      • 4.2.2.1. Mood Stabilizer
      • 4.2.2.2. Anticonvulsants
      • 4.2.2.3. Anti-Psychotic Drugs
      • 4.2.2.4. Anti-Depressant Drugs
      • 4.2.2.5. Anti-Anxiety Drugs
    • 4.2.3. By Disorder Type
      • 4.2.3.1. Bipolar I Disorder
      • 4.2.3.2. Bipolar II Disorder
      • 4.2.3.3. Cyclothymic Disorder
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Parenteral
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Online Pharmacies
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Disorder Type
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Bipolar Disorder Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Generic
      • 5.2.1.2. Branded
    • 5.2.2. By Drug Class
      • 5.2.2.1. Mood Stabilizer
      • 5.2.2.2. Anticonvulsants
      • 5.2.2.3. Anti-Psychotic Drugs
      • 5.2.2.4. Anti-Depressant Drugs
      • 5.2.2.5. Anti-Anxiety Drugs
    • 5.2.3. By Disorder Type
      • 5.2.3.1. Bipolar I Disorder
      • 5.2.3.2. Bipolar II Disorder
      • 5.2.3.3. Cyclothymic Disorder
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Parenteral
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Online Pharmacies
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Bipolar Disorder Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Generic
          • 5.3.1.2.1.2. Branded
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Mood Stabilizer
          • 5.3.1.2.2.2. Anticonvulsants
          • 5.3.1.2.2.3. Anti-Psychotic Drugs
          • 5.3.1.2.2.4. Anti-Depressant Drugs
          • 5.3.1.2.2.5. Anti-Anxiety Drugs
        • 5.3.1.2.3. By Disorder Type
          • 5.3.1.2.3.1. Bipolar I Disorder
          • 5.3.1.2.3.2. Bipolar II Disorder
          • 5.3.1.2.3.3. Cyclothymic Disorder
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Parenteral
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Bipolar Disorder Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Bipolar Disorder Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Bipolar Disorder Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Bipolar Disorder Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AbbVie Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. GlaxoSmithKline plc
    • 20.3.3. Eli Lilly and Company
    • 20.3.4. Janssen Pharmaceuticals, Inc.
    • 20.3.5. Astellas Pharma Inc.
    • 20.3.6. Bristol Myers Squibb Company
    • 20.3.7. Pfizer Inc.
    • 20.3.8. Novartis AG
    • 20.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 20.3.10. AstraZeneca PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 5. Global Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Bipolar Disorder Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. North America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 12. North America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13. North America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Bipolar Disorder Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 17. United States Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 18. United States Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 19. United States Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20. United States Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 23. Canada Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 24. Canada Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 25. Canada Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Canada Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 29. Mexico Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 30. Mexico Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 31. Mexico Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Mexico Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 35. Europe Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 36. Europe Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 37. Europe Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Europe Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Bipolar Disorder Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 42. Germany Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. Germany Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 44. Germany Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45. Germany Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 48. France Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 49. France Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 50. France Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. France Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 54. Italy Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Italy Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 56. Italy Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Italy Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 60. United Kingdom Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 61. United Kingdom Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 62. United Kingdom Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. United Kingdom Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 66. Russia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Russia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 68. Russia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Russia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 72. Netherlands Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 73. Netherlands Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 74. Netherlands Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Netherlands Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 78. Spain Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 79. Spain Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 80. Spain Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. Spain Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 84. Turkey Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Turkey Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 86. Turkey Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Turkey Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 90. Poland Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 91. Poland Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 92. Poland Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Poland Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 96. South America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 97. South America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 98. South America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. South America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Bipolar Disorder Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 103. Brazil Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. Brazil Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 105. Brazil Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. Brazil Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 109. Argentina Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 110. Argentina Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 111. Argentina Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112. Argentina Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 115. Asia-Pacific Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 116. Asia-Pacific Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 117. Asia-Pacific Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118. Asia-Pacific Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Bipolar Disorder Market Share (%), By Country, 2017-2031F
  • Figure 120. India Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 122. India Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 123. India Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 124. India Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. India Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 128. China Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. China Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 130. China Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. China Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 134. Japan Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Japan Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 136. Japan Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Japan Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 140. Australia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 141. Australia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 142. Australia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143. Australia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 146. Vietnam Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 147. Vietnam Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 148. Vietnam Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Vietnam Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 152. South Korea Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 153. South Korea Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 154. South Korea Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155. South Korea Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 158. Indonesia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 159. Indonesia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 160. Indonesia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. Indonesia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 164. Philippines Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 165. Philippines Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 166. Philippines Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167. Philippines Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 170. Middle East & Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Middle East & Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 172. Middle East & Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Middle East & Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Bipolar Disorder Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 177. Saudi Arabia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. Saudi Arabia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 179. Saudi Arabia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. Saudi Arabia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 183. UAE Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 184. UAE Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 185. UAE Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. UAE Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
  • Figure 189. South Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
  • Figure 190. South Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
  • Figure 191. South Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192. South Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Disorder Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023